Shanghai Innostar Biotechnology Valuation

Is 688710 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688710 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688710's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688710's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688710?

Key metric: As 688710 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688710. This is calculated by dividing 688710's market cap by their current earnings.
What is 688710's PE Ratio?
PE Ratio	39.1x
Earnings	CN¥146.65m
Market Cap	CN¥5.49b

688710 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.8x
Enterprise Value/EBITDA	18.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 688710's PE Ratio compare to its peers?

The above table shows the PE ratio for 688710 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	51.3x
688046 GemPharmatech	39.6x	27.9%	CN¥5.3b
301333 R&G PharmaStudies	44.1x	27.8%	CN¥5.2b
688222 HitGen	99.7x	20.3%	CN¥5.1b
688621 Beijing Sun-Novo Pharmaceutical Research	21.6x	29.5%	CN¥4.7b
688710 Shanghai Innostar Biotechnology	39.1x	n/a	CN¥5.5b

Price-To-Earnings vs Peers: 688710 is good value based on its Price-To-Earnings Ratio (39.1x) compared to the peer average (51.3x).

Price to Earnings Ratio vs Industry

How does 688710's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 688710 is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the Asian Life Sciences industry average (30.3x).

Price to Earnings Ratio vs Fair Ratio

What is 688710's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688710 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	39.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 688710's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥29.85

-10.1%

7.6%

Dong-E-E-JiaoLtd

CN¥37.2b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.97

-1.7%

17.1%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.9b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.29

-0.7%

16.7%